Nouri NeamatiAssociate Professor
Pharmacology and Pharmaceutical Sciences
School of Pharmacy |  | |
Education:
-
-
PhD 1995 Biomedical Sciences - University of Texas, GSBS, Houston
Postdoctoral Research Fellowship:
1995 - 1999 National Cancer Institute, National Institute of Health, Bethesda, Maryland
Started at USC: 2000 Research Topics: Structure-based and ligand-based drug design and discovery, database mining of small-molecules, anticancer and antiviral drug design, molecular pharmacology, chemoinformatics, inhibitors of protein-protein interaction, cell cycle, apoptosis, protein chemistry/enzymology.
Research Description
The overall goal of my lab is to design and develop novel anticancer and antiviral therapeutics useful for clinical trials. The major emphasize of my lab is to foster a multidisciplinary program in modern techniques for drug discovery. We are especially interested to identify small molecule inhibitors via three-dimensional data base searching and to identify drugs targeting HIV-1 integrase, apoptosis, angiogenesis, cell-cycle regulation and DNA repair pathways. Current projects include target identification and target validation, mechanism of drug action and identification of drug binding sites and microarray technology. We will participate in translational research program with the Norris Comprehensive Cancer Center on campus. Students and postdoctoral fellows interested in drug design and discovery, cellular and molecular pharmacology, medicinal and computational chemistry and molecular modeling are especially encouraged to visit the lab and discuss projects.
10 Selected Publications:
Click here to view all the publications for this faculty
Pathania D,Millard M,Neamati N - Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. - Adv Drug Deliv Rev [2009] Aug 27;(): PubMed
Wang P,Liu C,Sanches T,Zhong Y,Liu B,Xiong J,Neamati N,Zhao G - Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester. - Bioorg Med Chem Lett [2009] Aug 15;19(16):4574-8 PubMed
Grande F,Yamada R,Cao X,Aiello F,Garofalo A,Neamati N - Synthesis and biological evaluation of novel hydrazide based cytotoxic agents. - Expert Opin Investig Drugs [2009] May;18(5):555-68 PubMed
Martinez-Balibrea E,Plasencia C,Ginés A,Martinez-Cardús A,Musulén E,Aguilera R,Manzano JL,Neamati N,Abad A - A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. - Mol Cancer Ther [2009] Apr;8(4):771-8 PubMed
Serrao E,Odde S,Ramkumar K,Neamati N - Correction: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. - Retrovirology [2009] Apr 8;6(1):33 PubMed
Oshima T,Cao X,Grande F,Yamada R,Garofalo A,Louie S,Neamati N - Combination effects of SC144 and cytotoxic anticancer agents. - Anticancer Drugs [2009] Mar 24;(): PubMed
Martinez-Balibrea E,Martínez-Cardús A,Musulén E,Ginés A,Manzano JL,Aranda E,Plasencia C,Neamati N,Abad A - Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. - Int J Cancer [2009] Jan 21;(): PubMed
Cao X,Plasencia C,Kanzaki A,Yang A,Burke TR Jr,Neamati N - Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis. - Curr Cancer Drug Targets [2009] Mar;9(2):189-201 PubMed
Li H,Wang C,Sanchez T,Tan Y,Jiang C,Neamati N,Zhao G - Amide-containing diketoacids as HIV-1 integrase inhibitors: Synthesis, structure-activity relationship analysis, and biological activity. - Bioorg Med Chem [2009] Feb 7;(): PubMed
Serrao E,Odde S,Ramkumar K,Neamati N - Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. - Retrovirology [2009] Mar 5;6(1):25 PubMed
| |
